Shots:
- The NMPA has approved another NDA of Dovbleron (ROS1 tyrosine kinase inhibitor) for treating locally advanced or metastatic ROS1+ NSCLC. It was approved for those with ROS1+ NSCLC previously treated with ROS1 TKIs in Dec 2024
- The approval was supported by pivotal P-II (TRUST-I) study assessing safety, tolerability and efficacy of Dovbleron to treat NSCLC among Chinese population
- Study depicted durable efficacy, with cORR of 91% and intracranial cORR of 88% in ROS1 TKI-naïve patients (n=106); mDoR and mPFS were not achieved after 23.5 months of follow-up. Results were highlighted at ASCO 2024 & published in Journal of Clinical Oncology
Ref: Prnewswire | Image: Innovent
Related News:- Innovent Biologics Collaborates with Roche to Develop IBI3009 for SCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
